Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
5.692
Zitationen
12
Autoren
2004
Jahr
Abstract
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.
Ähnliche Arbeiten
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.444 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.535 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.488 Zit.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · 4.363 Zit.
Screening and Prostate-Cancer Mortality in a Randomized European Study
2009 · 3.990 Zit.
Autoren
Institutionen
- University of Toronto(CA)
- Princess Margaret Cancer Centre(CA)
- National Institute of Oncology(HU)
- Medical University of Lodz(PL)
- BC Cancer Agency(CA)
- Hôpital Européen Georges-Pompidou(FR)
- Hôpital Européen(FR)
- Institut Gustave Roussy(FR)
- Cancer Research UK(GB)
- Uppsala University Hospital(SE)
- Cancer Trials Australia(AU)
- Sidney Kimmel Comprehensive Cancer Center(US)
- Johns Hopkins University(US)